Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2015 August;63(4) > Minerva Cardioangiologica 2015 August;63(4):343-57





Rivista sulle Malattie del Cuore e dei Vasi

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752




Minerva Cardioangiologica 2015 August;63(4):343-57

lingua: Inglese

Next generation TAVI with the Lotus Valve System: a repositionable and fully retrievable transcatheter aortic valve prosthesis

Murdoch D. 1, 2, Shaw E. 1, 3, Raffel O. C. 1, 2, Walters D. L. 1, 2

1 Heart and Lung Institute, The Prince Charles Hospital, Brisbane, Australia;
2 School of Medicine, University of Queensland, Brisbane, Australia;
3 School of Medicine, The University of Sydney, Sydney, Australia


Transcatheter aortic valve implantation (TAVI) is the new standard of care for selected patients with severe symptomatic aortic stenosis who are at high risk for surgical aortic valve replacement (AVR), or are inoperable. Multicentre randomised controlled trials have demonstrated equivalent or superior clinical outcomes for TAVI compared to AVR in carefully selected patient cohorts. A number of important limitations were observed with early generation TAVI valves and their delivery systems, and rapid evolution of the technology continues. The Lotus Valve System aims to address a number of these limitations – it is repositionable and retrievable, and has an adaptive seal to prevent paravalvular aortic regurgitation. Early clinical outcomes for the Lotus Valve System have recently been published with promising results in terms of paravalvular regurgitation and repositionability.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail